Daniel Mertens

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 12

Top Venues

Cancers

Blood

International journal of cancer

Leukemia

This page only lists publications with an associated author ORCID identifier.

Publications

Jialei Qi, Sascha Endres, Deyan Yordanov Yosifov, Eugen Tausch, Rashmi Priyadharshini Dheenadayalan, Xiang Gao, Annika Müller, Christof Schneider, Daniel Mertens, Peter Gierschik, Martin Wist, Billy Michael Chelliah Jebaraj, Stephan Stilgenbauer
Acquired BTK mutations associated with resistance to non-covalent BTK inhibitors. Blood advances (2023)
Karol D Urbanek, Stephan Stilgenbauer, Daniel Mertens
To β or Not to β: How Important Is β-Catenin Dependent and Independent WNT Signaling in CLL? Cancers 15 (1) (2022)
Karol D Urbanek, Stephan Stilgenbauer, Daniel Mertens
To β or Not to β: How Important Is β-Catenin Dependent and Independent WNT Signaling in CLL? Cancers 15 (1) (2022)
Christine Wolf, Carsten Maus, Michael R O Persicke, Katharina Filarsky, Eugen Tausch, Christof Schneider, Hartmut Döhner, Stephan Stilgenbauer, Peter Lichter, Thomas Höfer, Daniel Mertens
Modeling the B-cell receptor signaling on single cell level reveals a stable network circuit topology between nonmalignant B cells and chronic lymphocytic leukemia cells and between untreated cells and cells treated with kinase inhibitors. International journal of cancer 151 (5) (2022)
Karol D Urbanek, Stephan Stilgenbauer, Daniel Mertens
To β or Not to β: How Important Is β-Catenin Dependent and Independent WNT Signaling in CLL? Cancers 15 (1) (2022)
Billy Michael Chelliah Jebaraj, Annika Müller, Rashmi Priyadharshini Dheenadayalan, Sascha Endres, Philipp M Roessner, Felix Seyfried, Claudia Walliser, Martin Wist, Jialei Qi, Eugen Tausch, Daniel Mertens, Judith A Fox, Klaus-Michael Debatin, Lueder Hinrich Meyer, Pietro Taverna, Martina Seiffert, Peter Gierschik, Stephan Stilgenbauer
Evaluation of vecabrutinib as a model for non-covalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia. Blood (2021)
Deyan Yordanov Yosifov, Johannes Bloehdorn, Hartmut Döhner, Peter Lichter, Stephan Stilgenbauer, Daniel Mertens
DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy. Scientific data 7 (1) (2020)
Deyan Yordanov Yosifov, Irina Idler, Nupur Bhattacharya, Michaela Reichenzeller, Viola Close, Daria Ezerina, Annika Scheffold, Billy Michael Chelliah Jebaraj, Sabrina Kugler, Johannes Bloehdorn, Jasmin Bahlo, Sandra Robrecht, Barbara Eichhorst, Kirsten Fischer, Anja Weigel, Hauke Busch, Peter Lichter, Hartmut Döhner, Tobias P Dick, Stephan Stilgenbauer, Daniel Mertens
Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL. Leukemia 34 (1) (2019)
Jan-Philipp Mallm, Murat Iskar, Naveed Ishaque, Lara C Klett, Sabrina J Kugler, Jose M Muiño, Vladimir B Teif, Alexandra M Poos, Sebastian Großmann, Fabian Erdel, Daniele Tavernari, Sandra D Koser, Sabrina Schumacher, Benedikt Brors, Rainer König, Daniel Remondini, Martin Vingron, Stephan Stilgenbauer, Peter Lichter, Marc Zapatka, Daniel Mertens, Karsten Rippe
Linking aberrant chromatin features in chronic lymphocytic leukemia to transcription factor networks. Molecular systems biology 15 (5) (2019)
Viola Close, William Close, Sabrina Julia Kugler, Michaela Reichenzeller, Deyan Yordanov Yosifov, Johannes Bloehdorn, Leiling Pan, Eugen Tausch, Mike-Andrew Westhoff, Hartmut Döhner, Stephan Stilgenbauer, Franz Oswald, Daniel Mertens
FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL. Blood 133 (8) (2018)
Daniel Mertens, Stephan Stilgenbauer
Ibrutinib-resistant CLL: unwanted and unwonted! Blood 129 (11) (2018)
Christine Wolf, Angela Garding, Katharina Filarsky, Jasmin Bahlo, Sandra Robrecht, Natalia Becker, Manuela Zucknick, Arefeh Rouhi, Anja Weigel, Rainer Claus, Dieter Weichenhan, Barbara Eichhorst, Kirsten Fischer, Michael Hallek, Florian Kuchenbauer, Christoph Plass, Hartmut Döhner, Stephan Stilgenbauer, Peter Lichter, Daniel Mertens
NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib. International journal of cancer 142 (2) (2017)

Daniel Mertens.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Daniel Mertens